Press Releases

SALT LAKE CITY, Feb. 9, 2012 /PRNewswire/ -- Zions Direct, the online broker-dealer that allows its customers to purchase FDIC – insured Certificates of Deposit in its daily web-based auctions, announces its weekly auction results. In auctions closed from February 1, 2012 to February 7, 2012, investors purchasing FDIC-insured CDs in the auctions received average yields 0.60 percentage points, or 60 basis points, higher than average yields on similar CDs as reported in Informa Research Services Top 50 National APYs, February 7, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20110914/SF68814LOGO)

Zions Direct regularly publishes data from CDs auctioned at Zions Direct Auctions compared against similar securities offered in the marketplace in their Market Snapshot. Since February 2007, Zions Direct has auctioned over 1.1 billion dollars in more than 4,000 fixed-income auctions.

ZIONS DIRECT AUCTIONS MARKET SNAPSHOT

FDIC-Insured Certificate of Deposit Data*

Total Average Difference (basis points): 60

For more information on Zions Direct and the Market Snapshot go to zionsdirect.com to sign up to receive the free weekly newsletter or visit think.zionsdirect.com to view a Market Snapshot archive.

THE INFORMATION INCLUDED IS NOT INTENDED TO SERVE AS THE BASIS FOR INVESTMENT DECISIONS. PAST PERFORMANCE IS NOT AN INDICATION OF FUTURE RESULTS.

*See Additional Disclaimer for data source information.

About Zions Direct

Zions Direct is a broker-dealer that specializes in offering securities for self-directed and fixed income-focused investors. Zions Direct allows retail investors to buy FDIC-insured certificates of deposit, corporate and municipal bonds, and other investment products through their web-based Bond Store and auction platforms. In addition, clients can invest in stocks, mutual funds, and exchange-traded funds online or through a Zions Direct financial representative.

Investment products and services offered through Zions Direct, member of FINRA/SIPC, a non-bank subsidiary of Zions Bank are NOT insured by the FDIC or any federal or state governmental agency, are NOT deposits or other obligations of, or guaranteed by, Zions Bancorporation or its affiliates, and MAY be subject to investment risks, including the possible loss of principal value or amount invested. FDIC-insured CDs are insured up to $250,000 per individual account holder per bank.

Additional Disclaimer

Zions Direct Auction CD yields are from auctions ending February 1, 2012 to February 7, 2012. A weighted average is calculated when multiple CDs of similar terms are sold through platform. FDIC-insured CDs with terms of 1 month are noted as 1 month; 2 months are noted as 2 months; 3 – 4 months are noted as 3 months; 5 – 7 months as 6 months; 8 – 10 months as 9 months; 11 – 17 months as 1 year; 18 – 29 months as 2 year; 48 – 71 months as 5 years.

Top 50 National APYs – Top 50 U.S. bank and thrift holding companies by deposits. CD Rates Average APYs are based on certificate of deposit accounts for $25,000. Copyright 2012 Informa Research Services, Inc as a part of their Interest Rate Review – Retail. Report dated February 7, 2012.

SOURCE Zions Direct

MENLO PARK, Calif., Feb. 9, 2012 /PRNewswire/ -- Health Fidelity, Inc. has closed a Series A financing round led by Charter Life Sciences of Santa Clara, CA.  The funds will be used to develop and market its clinical natural language processing (NLP) platform. 

Health Fidelity's platform allows healthcare enterprises to extract data from the vast amount of clinical data, including narrative data, which they collect.  "As much as 80 percent of medical information stored by healthcare organizations is unstructured and therefore unusable for analytics," said Dan Riskin, M.D., CEO of Health Fidelity.  "Our technology transforms the data into usable form.  Our Fidelity Platform is a robust, high quality platform in the cloud that is easy to use and quick to integrate with existing applications."

Health Fidelity expects clinical NLP to gain increasing attention as healthcare executives grapple with upcoming requirements for meaningful use of healthcare data, the conversion to ICD-10 coding and the new accountable care organizations (ACO).  "The industry must measure and improve the quality of healthcare while controlling costs.  Use of previously inaccessible medical data will be critical to these efforts," said Dr. Riskin.

"Natural language processing is a rapidly expanding market and will be vital to enable health systems to address new quality standards," said Fred Schwarzer, Managing Partner at Charter Life Sciences.  "With industry leading technology, patents, and team, Health Fidelity is uniquely situated to take advantage of this opportunity."

The Health Fidelity platform is built on one of the most reliable and heavily used clinical NLP engines, which leaves it poised to be a market leader.  Earlier this month, Health Fidelity announced an exclusive license to commercialize Columbia University's MedLEE NLP technology in healthcare.  With two years of experience developing commercial products with the MedLEE technology, Health Fidelity can move quickly to enable solution partners to get their products to market.

About Charter Life Sciences

Charter Life Sciences ("CLS") is a life sciences venture capital firm with offices in Santa Clara, California and Cincinnati, Ohio. CLS focuses on providing the initial venture capital to companies that are developing innovative products for significant unmet medical needs. The CLS team draws on its extensive medical, operational and start-up company experience to work collaboratively with its portfolio companies to develop their clinical, operational and financing strategies. For additional information on CLS, please visit www.clsvc.com.

About Health Fidelity

Health Fidelity, Inc. (www.healthfidelity.com) offers a clinical natural language processing (NLP) platform that enables medical practitioners and administrators to effectively make use of the wealth of currently unusable medical information they collect. The company works with solutions partners to provide end-user applications built on the robust clinical data our powerful platform extracts. As a result, end-users can make better medical decisions, monitor and improve the quality of care, and enable R&D that will bring us to the next frontier in healthcare.

For partnership inquiries, contact Lauryn Jones at partnership@healthfidelity.com.

Media ContactChristopher CapotKNB Communications203-379-8019, ccapot@knbpr.com

SOURCE Health Fidelity, Inc.